Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 30, Issue 1, pp 73–76 | Cite as

A randomised phase II study of carmustine alone or in combination with tomour necrosis factor in patients with advanced melanoma

  • Alison L. Jones
  • Mary E. R. O'Brien
  • Alison Lorentzos
  • Christine Viner
  • Angela Hanrahan
  • Jaqualyn Moore
  • John L. Millar
  • Martin E. Gore
Short Communication Tumour Necrosis Factor, Carmustine, Melanoma

Summary

Laboratory data suggest a synergistic interaction between carmustine (BCNU) and tumour necrosis factor (TNF) in melanoma. We therefore studied the activity of 200 mg/m2 BCNU given alone or in combination with 88 μg/m2 recombinant human TNF-alpha (rhTNFα) as a daily i. v. infusion for 5 days at 48-day intervals to patients with metastatic melanoma. In this randomised phase II trial, the rate of response to BCNU alone was 20% [95% confidence interval (CI), 2%–38%], and this was not improved by the addition of TNF (response rate, 10.5%; 95% CI, 1.3%–33%). Toxicity was higher in the combination arm, and there was no difference in survival.

Keywords

Confidence Interval Melanoma Cancer Research Tumour Necrosis Tumour Necrosis Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ahmann DL (1976) Nitrosoureas in the management of disseminated malignant melanoma. Cancer Treat Rep 60: 747Google Scholar
  2. 2.
    Alexander RB, Nelson WG, Coffey DS (1987) Synergistic enhancement by tumour necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II. Cancer Res 47: 2403Google Scholar
  3. 3.
    Beutler B, Cerami A (1987) Cachetin: more than a tumour necrosis factor. N Engl J Med 316: 379Google Scholar
  4. 4.
    Carswell EA, Old LJ, Kassel RA, Green S, Fiore N, Williamson B (1973) An endotoxin-induced serum factor that causes necrosis of tumours. Proc Natl Acad Sci USA 72: 3666Google Scholar
  5. 5.
    Comis RL (1976) DTIC (NSC-453-88) in malignant melanoma: a perspective. Cancer Treat Rep 60: 165Google Scholar
  6. 6.
    Creagan ET, Ahmann DL, Frytal S, Long HJ, Chang MN, Ihi LM (1987) Three consecutive phase II studies of recombinant interferon alpha-2a in advanced malignant melanoma. Cancer 59: 638Google Scholar
  7. 7.
    Das AK, Walter PJ, Buckley NJ, Poulton SHM (1989) Recombinant human tumour necrosis factor alone and in combination with chemotherapeutic agents. Arch Surg 124: 107Google Scholar
  8. 8.
    Fransen L, Ruysshaert MR, Van der Heyden J, Fiers W (1975) Recombinant tumour necrosis factor, species specificity for a variety of human and transformed cell lines. Cell Immunol 100: 20Google Scholar
  9. 9.
    Helson L, Green S, Carswell EA, Old LJ (1975) Effect of tumour necrosis factor on cultured melanoma cells. Nature 258: 731Google Scholar
  10. 10.
    Jones AL, Selby P (1989) Tumour necrosis factor: clinical relevance. Cancer Surv 8: 817Google Scholar
  11. 11.
    Jones AL, Millar JL, Millar BC, Powell B, Selby P, Winkley A, Lakhani S, Gore ME, McElwain TJ (1990) Enhanced anti-tumour activity of carmustine (BCNU) with tumour necrosis factor in vitro and in vivo. Br J Cancer 62: 776Google Scholar
  12. 12.
    Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 437–481Google Scholar
  13. 13.
    Lakhani S, Selby P, Bliss JM, Perren TJ, Gore ME, McElwain TJ (1990) Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit. Br J Cancer 61: 330Google Scholar
  14. 14.
    McClay EF, Mastrangelo MJ (1988) Systemic chemotherapy for metastatic melanoma. Semin Oncol 15: 569Google Scholar
  15. 15.
    Rosenberg SA, Lotze MT, Muul LM, et al (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin 2 or high dose interleukin 2 alone. N Engl J Med 316: 889Google Scholar
  16. 16.
    Selby P, Hobbs S, Fearon K, Viner C, Jackson E, Jones A, Newell D, Humphrey SJ, Goy G, Calvert AH, McElwain TJ (1987) Tumour necrosis factor in man: clinical and biological observations. Br J Cancer 56: 803Google Scholar
  17. 17.
    World Health Organisation (1978) Handbook for reporting results of cancer treatment. Offset publication 48. WHO, GenevaGoogle Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • Alison L. Jones
    • 1
  • Mary E. R. O'Brien
    • 1
  • Alison Lorentzos
    • 1
  • Christine Viner
    • 1
  • Angela Hanrahan
    • 1
  • Jaqualyn Moore
    • 1
  • John L. Millar
    • 1
  • Martin E. Gore
    • 1
  1. 1.Department of MedicineRoyal Marsden HospitalLondonUK

Personalised recommendations